The Doctors Who Carry Out China's Forced Organ Harvesting: Dr. Harold King
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
16 hours ago
- New York Post
FDA sends warning to 5 sunscreen brands including Supergoop — why they could be pulled from shelves
Some of the summer's hottest beauty products just got burned. 'Beware of sunscreen products in mousse form because they might not be effective,' the Food and Drug Administration cautioned in a post on X this week. The alert follows a wave of warning letters the agency sent to Supergoop!, Vacation Inc. and three other popular brands, accusing them of peddling whipped, mousse and foam sunscreens that flout federal laws. Advertisement 3 Mousse sunscreen may be popular, but the FDA says the product doesn't comply with federal laws regarding over-the-counter drugs. Supergoop! Before you send your beloved sunscreens packing, let's break down the FDA's warnings. The letters — also sent to Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals (makers of TiZo sunscreen) — claim the frothy formulas are 'misbranded.' That's because sunscreens are classified as over-the-counter drugs in the US — and that comes with strict regulations around how they're formulated and marketed. Advertisement Per FDA rules, sunscreens can only be sold as oils, lotions, creams, gels, butters, pastes, ointments, sticks, sprays or powders — not foams, mousses, or whips. To use those formats legally, companies must submit a new drug application with sufficient data proving their safety and effectiveness. 'There are no FDA-approved applications in effect for your drug products,' the agency wrote. Advertisement 3 Because they're marketed to prevent sunburns and skin cancer, sunscreens are regulated as drugs. Vacation The FDA also took aim at Vacation Inc.'s 'Classic Whip Sunscreen,' sold in containers that look like whipped cream cans and advertised as 'dessert for your skin.' 'Packaging drug products in containers that resemble food containers commonly used by adults and children can mislead consumers into mistaking the products for food, which is of particular concern as this increases the risk of accidental ingestion,' the agency warned. Advertisement But the FDA's heat doesn't necessarily mean these fluffy formulas fall short at blocking burns or reducing skin cancer risk. 'The letter does not state that mousse-format sunscreens are less effective or unsafe, nor does it question the quality or performance of our formulation,' Kalani Sunwear told Cosmetics Business, adding that it's 'Sun Mousse SPF 50 is developed and manufactured in Sweden to the highest European standards.' A Supergoop! spokesperson told The Post that the warning 'is focused on product labeling and has nothing to do with its safety, effectiveness or formula,' and added that the company is 'working closely with the FDA to resolve this matter.' 3 To legally sell sunscreens in mousse, foam, or whipped form, companies have to file new drug applications, the FDA said. TikTok/supergoop Still, some outside experts aren't so sure about the whipped format. 'SPF is determined by applying 2 mg/cm^2, which is measured by weight, not volume,' Ava Perkins, a cosmetic chemist and US sunscreen expert, told The Cut. 'Because these mousse sunscreens have so much air incorporated into the product, it can be challenging to know if you're putting on enough, even if it seems like a lot is being dispensed,' she added. Advertisement The FDA's letters, dated August 6, gave each company 15 working days to explain how they plan to fix the issues or prove they're not in violation. Kalani Sunwear has already started taking action, temporarily pulling its mousse-format sunscreen from its US website 'to ensure full compliance with the regulations,' according to CBS News. The Post has reached out to Vacation, Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals for comment.
Epoch Times
a day ago
- Epoch Times
The Doctors Who Carry Out China's Forced Organ Harvesting: Dr. Harold King
NTD's Lee Hall sits down with Dr. Harold King, European director of Doctors Against Forced Organ Harvesting. King talks about the horrific realities of organs being forcibly taken from innocent people who are left for dead, the massive profits the Chinese regime is making from this, how the international community can stand agai...
Medscape
a day ago
- Medscape
RA May Be a Causal Driver of Idiopathic Pulmonary Fibrosis
TOPLINE: Rheumatoid arthritis (RA) was causally linked to the development of idiopathic pulmonary fibrosis, with shared plasma factors CC motif chemokine ligand 2 (CCL2) and CXC motif chemokine ligand 2 (CXCL2) identified as potential diagnostic biomarkers. METHODOLOGY: Idiopathic pulmonary fibrosis shares inflammatory and fibrotic features with RA, but the causal relationship is unknown. Researchers conducted a bidirectional Mendelian randomization analysis using genome-wide association study data from European cohorts to explore causality between the two conditions. They analyzed the data of 14,361 patients with RA and 42,923 control individuals as well as data from 1028 patients with idiopathic pulmonary fibrosis and 196,986 control individuals. Significant single nucleotide polymorphisms were selected as instrumental variables, and the inverse variance weighted method was used for analysis, supplemented by Mendelian randomization-Egger, weighted median, and sensitivity tests. Transcriptomic and single-cell RNA sequencing data from patients with RA vs control individuals were analyzed to identify shared genetic features. TAKEAWAY: Mendelian randomization analysis indicated that RA increases the risk for idiopathic pulmonary fibrosis (inverse variance weighted method: odds ratio, 1.156; P = .002). However, the reverse analysis found no effect of idiopathic pulmonary fibrosis on RA. CCL2 and CXCL2 were identified as key shared biomarkers in transcriptomic analysis. Biomarker validation in 40 individuals with RA vs 40 controls showed higher levels of CCL2 and CXCL2 in the plasma of patients with RA (P < .05 for both), with area under the curve values from the receiver operating characteristic analysis indicating diagnostic potential. IN PRACTICE: "RA causally contributes to [idiopathic pulmonary fibrosis], with CCL2 and CXCL2 as shared biomarkers exhibiting diagnostic potential. Elevated in RA-specific cell types and linked to inflammation, they offer insights into disease mechanisms and early detection strategies for RA-associated idiopathic pulmonary fibrosis," the authors concluded. SOURCE: The study was led by Xixi Pan, Taizhou Hospital of Zhejiang Province affiliated with Wenzhou Medical University in Linhai, China. It was published online on July 25, 2025, in Med Research. LIMITATIONS: The study's findings might only apply to groups similar to those in the genome-wide association study datasets, with some possible overlap in samples and remaining confounding factors. Using publicly available datasets may limit how detailed the phenotypic characterization is. The small validation group may be underpowered to detect small effects, and the absence of epigenetic analysis and functional tests restricts understanding of the underlying mechanisms. DISCLOSURES: The study was supported by grants from the Joint TCM Science & Technology Projects of National Demonstration Zones for Comprehensive TCM Reform, Zhejiang Provincial Natural Science Foundation, General Scientific Research Project of the Zhejiang Provincial Department of Education, and others. The authors declared having no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
